{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Percentage of patients experiencing treatment-related grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Olaparib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Percentage of Patients Experiencing Treatment-related Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}